



ESMO 2019 Industry Satellite Symposium

INTEGRATING PRECISION MEDICINE: ARE WE READY FOR A PARADIGM SHIFT IN ADVANCED UROTHELIAL CARCINOMA?

**FRIDAY
27 SEPTEMBER 2019
18:00-20:00**

Hall 3
Santander Auditorium
Fira Gran Via
Barcelona, Spain

SCIENTIFIC COMMITTEE

Maria De Santis **GERMANY**
Joaquim Bellmunt **USA**

FACULTY

Eva Comperat **FRANCE**
Yohann Lorient **FRANCE**
Shahrokh Shariat **AUSTRIA**
Arlene Siefker-Radtke **USA**

OVERALL LEARNING OBJECTIVES

After attending this meeting, participants should be able to:

- Differentiate current metastatic urothelial carcinoma treatment options and describe their applicability in clinical practice
- Evaluate tumour biology, the role of biomarkers, and the challenges of advanced urothelial carcinoma from a multidisciplinary perspective
- Describe how current research may drive therapeutic decisions for patients with advanced urothelial carcinoma in the future

PROGRAM

TIME	SESSION	FACULTY
18:00-18:10	Introduction - Welcome to the future?	Maria De Santis and Joaquim Bellmunt
18:10-18:35	The path to now: how did the current management of advanced urothelial carcinoma develop?	Shahrokh Shariat
18:35-19:00	What is today's understanding of the molecular landscape of advanced urothelial carcinoma?	Eva Comperat
19:00-19:25	How could targeted therapies influence the management landscape?	Yohann Lorient
19:25-19:50	Can the molecular biology knowledge be integrated into the clinical practice today?	Arlene Siefker-Radtke
19:50-20:00	Closing remarks - Advanced urothelial carcinoma 2.0: are we ready for a paradigm shift?	Joaquim Bellmunt and Maria De Santis



With the support of Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA
Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse, Belgium
Date of preparation: June 2019
CP-95569

